Patents by Inventor Ingrid Wertz

Ingrid Wertz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTAC ANTIBODY CONJUGATES AND METHODS OF USE
    Publication number: 20230330102
    Abstract: The subject matter described herein is directed to antibody-PROTAC conjugates (PACs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.
    Type: Application
    Filed: May 2, 2023
    Publication date: October 19, 2023
    Inventors: Thomas Pillow, Jack Sadowsky, Leanna Staben, Steven Staben, Binqing Wei, Ingrid Wertz, Pragya Adhikari, Nicole Blaquiere, Peter Dragovich, Wayne Fairbrother
  • PROTAC antibody conjugates and methods of use
    Patent number: 11666581
    Abstract: The subject matter described herein is directed to antibody-PROTAC conjugates (PACs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: June 6, 2023
    Assignee: Genentech, Inc.
    Inventors: Thomas Pillow, Jack Sadowsky, Leanna Staben, Steven Staben, Binqing Wei, Ingrid Wertz, Pragya Adhikari, Nicole Blaquiere, Peter Dragovich, Wayne Fairbrother
  • CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE
    Publication number: 20230067037
    Abstract: The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.
    Type: Application
    Filed: April 23, 2021
    Publication date: March 2, 2023
    Applicant: Genentech, Inc.
    Inventors: Peter DRAGOVICH, Thomas PILLOW, Robert Anthony BLAKE, Ingrid WERTZ
  • COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR
    Publication number: 20210213130
    Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
    Type: Application
    Filed: December 21, 2020
    Publication date: July 15, 2021
    Applicant: GENENTECH, INC.
    Inventors: Gail Lewis Phillips, Deepak Sampath, Ingrid Wertz
  • Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor
    Patent number: 10898570
    Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Gail Lewis Phillips, Deepak Sampath, Ingrid Wertz
  • Piperidine derivatives as inhibitors of ubiquitin specific protease 7
    Patent number: 10766903
    Abstract: The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 8, 2020
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Colin O'Dowd, Tim Harrison, Peter Hewitt, Shane Rountree, Miel Hugues, Frank Burkamp, Linda Duncan Jordan, Matthew Helm, Fabio Broccatelli, James John Crawford, Lewis Gazzard, Ingrid Wertz, Wendy Lee
  • PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7
    Publication number: 20190256518
    Abstract: The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.
    Type: Application
    Filed: October 20, 2017
    Publication date: August 22, 2019
    Inventors: Colin O'DOWD, Tim HARRISON, Peter HEWITT, Shane ROUNTREE, Miel HUGUES, Frank BURKAMP, Linda Duncan JORDAN, Matthew HELM, Fabio BROCCATELLI, James John CRAWFORD, Lewis GAZZARD, Ingrid WERTZ, Wendy LEE
  • PROTAC ANTIBODY CONJUGATES AND METHODS OF USE
    Publication number: 20190175612
    Abstract: The subject matter described herein is directed to antibody-PROTAC conjugates (PACs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.
    Type: Application
    Filed: November 19, 2018
    Publication date: June 13, 2019
    Inventors: Thomas Pillow, Jack Sadowsky, Leanna Staben, Steven Staben, Binqing Wei, Ingrid Wertz, Pragya Adhikari, Nicole Blaquiere, Peter Dragovich, Wayne Fairbrother
  • COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR
    Publication number: 20180140700
    Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 24, 2018
    Inventors: Gail Lewis Phillips, Deepak Sampath, Ingrid Wertz
  • METHODS OF TREATMENT WITH TASELISIB
    Publication number: 20160375033
    Abstract: Taselisib (GDC-0032) induces the degradation of mutant-p110 alpha protein. Methods for selecting patients with mutant PI3K tumors for treatment with taselisib are described.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 29, 2016
    Applicant: Genentech, Inc.
    Inventors: Kyle Edgar, Lori Friedman, Deepak Sampath, Kyung Song, Ingrid Wertz, Timothy Wilson
  • BIOMARKERS FOR TREATMENT WITH ANTI-TUBULIN CHEMOTHERAPEUTIC COMPOUNDS
    Publication number: 20160136295
    Abstract: Provided herein are biomarkers for predicting sensitivity to treating cancer with anti-tubulin chemotherapeutic agents.
    Type: Application
    Filed: July 2, 2014
    Publication date: May 19, 2016
    Applicant: GENENTECH, INC.
    Inventor: Ingrid Wertz